Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-06372865 in Healthy Adults
NCT03351751Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in epilepsy, generalized anxiety disorder (GAD) and chronic low back pain (CLBP) comparing Placebo with PF-06372865 (2 arms). Primary endpoints: Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs), Change From Baseline in Vital Signs and 6 more. Started Nov 2017; status: completed.
02
Drugs
darigabat
03
Conditions
epilepsygeneralized anxiety disorder (GAD)chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT03351751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03351751.